Compare Novo Nordisk A/S (NVO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Under Armour Inc Class A — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Novo Nordisk A/S is far larger — about 79.9× Under Armour Inc Class A's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Under Armour Inc Class A for 99 Days on average.
| NVO | UAA | |
|---|---|---|
Market Cap | $165.31B | $2.07B |
Volume | 11,432,838 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $8.14 |
52-Week Low | $35.29 | $4.17 |
Typical Hold Time | 116 Days | 99 Days |
Enterprise Value | $179.56B | $3.05B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and ROE (-29.82%) despite beating Q2 2026 EPS estimates. Recent news highlights the company's brand transformation efforts amid softer demand, with management maintaining profitability outlook despite revenue cuts.
The stock presents a high-risk opportunity with analyst consensus pointing to 18.6% upside to the $5.79 price target. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures. The 27% buy rating suggests cautious optimism, but investors need clear evidence of sustainable margin improvement and revenue stabilization for meaningful upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
